Life ScienceCompany
LEO PDE4 Inhibitor Ownership
Who owns LEO PDE4 Inhibitor?
LEO PDE4 Inhibitor is owned by UNION therapeutics A/S. It was acquired on July 21, 2020.
LEO PDE4 Inhibitor Business Overview
Where is LEO PDE4 Inhibitor headquartered?
LEO PDE4 Inhibitor is headquartered in Ballerup, Denmark.
What sector is LEO PDE4 Inhibitor in?
LEO PDE4 Inhibitor is a life science company.
Life Science M&A Summary in 2020
Out of 60 sectors in the Mergr database, life science ranked 7 in number of deals in 2020. The largest life science acquisition in 2020 was Alexion Pharmaceuticals - which was acquired by AstraZeneca for $39.0B.
Join Mergr to view all 290 acquisitions of life science companies in 2020, including 23 acquisitions by private equity firms, and 267 by strategics.